Canopy Growth stock tumbles after announcing $200 million share sale plan
Broadwood Partners, L.P. has increased its stake in Staar Surgical Co. (NASDAQ:STAA) with a series of stock purchases. According to a recent SEC filing, the firm acquired a total of 201,844 shares of Staar Surgical’s common stock. The transactions, which took place on March 18 and March 20, 2025, were executed at prices ranging from $16.58 to $17.99 per share, totaling approximately $3.6 million. The purchases come as the stock trades near its Fair Value according to InvestingPro analysis, with the shares down over 54% in the past year and currently trading at $17.92.
The purchases were made by Broadwood Partners, L.P., a significant shareholder in Staar Surgical, and may be indirectly beneficially owned by Broadwood Capital, Inc. and Neal C. Bradsher, the President of Broadwood Capital. The transactions reflect Broadwood’s ongoing interest in Staar Surgical, a company specializing in ophthalmic goods. Following these transactions, Broadwood Partners holds over 12 million shares of Staar Surgical. InvestingPro data shows the company maintains strong liquidity with a current ratio of 5.23 and holds more cash than debt, though analysts have recently revised earnings expectations downward. Get the full analysis and 7 additional key insights with an InvestingPro subscription.
In other recent news, STAAR Surgical ’s fourth-quarter 2024 results fell short of expectations, leading to a series of analyst reactions. Jefferies downgraded the stock and significantly slashed its price target to $18, reflecting concerns over the company’s near-term revenue prospects and reliance on the Chinese market. Similarly, Canaccord Genuity reduced its price target to $17 while maintaining a Hold rating, citing a low valuation compared to peers and challenges in the Chinese market. Stifel also lowered its price target to $20, maintaining a Buy rating, but noted inventory issues in China that may take time to resolve.
Additionally, Piper Sandler maintained a Neutral rating with a $16 target, highlighting executive changes, including the resignation of CFO Patrick Williams and the appointment of Deborah Andrews as Interim CFO. BTIG echoed a Neutral stance amid these leadership changes, pointing to cost-saving measures that are not expected to impact revenue growth. These developments have created uncertainty among investors, with analysts watching for signs of recovery and stabilization, particularly in the Chinese market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.